SAN DIEGO, Aug. 24, 2015 /PRNewswire/ -- Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) reported today the successful implementation of its gene silencing technology, covered by patent # 8,263,571, in killing cancer stem cells. The technology involves using RNA interference to block expression of the cancer-sustaining gene Brother of the Regulator of Imprinted Sites (BORIS) by a process termed "gene silencing".
In a publication in the peer-reviewed journal PLoS One, independent researchers at the Lausanne University Hospital, Switzerland reported that blocking the BORIS gene results in a profound reduction of breast cancer and colon cancer stem cells. In addition, the researchers verified the original findings that BORIS is a "master orchestrator" of the process of tumor formation, growth and metastasis.
"From 2006-2008, together with a team of scientists from the Institute of Molecular Medicine and the National Institutes of Health, we published that vaccinating against BORIS results in immune response against and tumor regression in breast cancer, melanoma, and glioma,,. Subsequently we published that gene silencing of BORIS can be utilized to selectively kill breast cancer cells," stated Thomas Ichim, Ph.D, Chief Scientific Officer of Regen BioPharma. "As we saw in the recent publication, the role of BORIS as an "Achilles Heel" of cancer is becoming more and more apparent. We are currently in the process of advancing our gene-silencing based approaches, in part by leveraging lessons we are learning during dCellVax development, in order to file an IND for BORIS gene silencing technology."
Regen BioPharma is currently using gene silencing for immune modulation in its dCellVax program, as well as various nuclear receptors in its other cancer stem cell targeting program.
"The current programs in development, HemaXellerate, dCellVax, and gene silencing of nuclear receptors are all intertwined so that experiences from one program help to accelerate the other programs. By collaborating with academic and corporate entities on a continual basis, we strive to be at the cutting edge of science, while rapidly aiming to commercialize and add value to our science," said David Koos, PhD, Chairman and CEO of Regen BioPharma.
ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
 Alberti et al. PLoS One. 2015; 10(7): e0132977. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506091/pdf/pone.0132977.pdf
 Loukinov et al. J Cell Biochem. 2006 Aug 1;98(5):1037-43. http://www.ncbi.nlm.nih.gov/pubmed/16741971
 Ghochikyan et al. J Immunol. 2007 Jan 1;178(1):566-73. http://www.ncbi.nlm.nih.gov/pubmed/17182597
 Mkrtichyan et al. Gene Ther. 2008 Jan;15(1):61-4. http://www.ncbi.nlm.nih.gov/pubmed/17972923
 Dougherty et al. Biochem Biophys Res Commun. 2008 May 23;370(1):109-12. http://www.ncbi.nlm.nih.gov/pubmed/18355444
SOURCE Regen BioPharma, Inc.